文献速递认知障碍与痴呆

阿杜那单抗治疗早期阿尔茨海默病的成本效果与基于价值的定价

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
PubMed 文献 · Neurology · 2022-01-12

本研究采用马尔可夫模型,比较阿杜那单抗联合支持治疗与单独支持治疗在早期阿尔茨海默病患者终生 horizon 内的成本效果。从卫生系统和修正社会视角分析,阿杜那单抗每患者仅增加0.154个质量调整生命年(QALY)和0.201个等值生命年获益(evLYG),但额外成本约204,000美元;按年定价56,000美元,每QALY成本达1.33百万美元,远高于常用阈值;满足成本效果阈值的年定价为2,950至8,360美元。

要点

  • 阿杜那单抗每患者仅增加0.154个QALY和0.201个evLYG,额外成本约204,000美元。
  • 按年定价56,000美元,每QALY成本为1.33百万美元(卫生系统视角),远超常用阈值。
  • 满足常用成本效果阈值的年定价为2,950至8,360美元,较上市价折扣85%-95%。

核心结论

  • 接受阿杜那单抗治疗的患者健康结局改善极小但成本可观,增量成本效果比远超常用价值阈值,即使采用乐观疗效假设亦然。
  • 目前证据提示阿杜那单抗年定价56,000美元与其临床获益不合理匹配。

研究设计与样本

  • 开发马尔可夫模型,比较阿杜那单抗联合支持治疗与单独支持治疗,终生时间 horizon,从卫生系统和修正社会视角分析。
  • 模型追踪疾病严重程度和护理场所,计算增量成本效果比并进行阈值分析。

主要发现

  • 基于两项关键试验汇总数据,接受阿杜那单抗治疗的患者在阿尔茨海默病早期阶段多停留4个月。
  • 从卫生系统视角,每患者增加0.154个QALY和0.201个evLYG,额外成本约204,000美元;修正社会视角结果相似。
  • 按年定价56,000美元,卫生系统视角每evLYG成本1.02百万美元至每QALY成本1.33百万美元;修正社会视角每evLYG成本938,000美元至每QALY成本1.27百万美元。
  • 满足常用成本效果阈值的年定价为2,950至8,360美元,较上市价折扣85%-95%。
  • 仅基于提示获益的试验疗效估计,每QALY增量成本均值超过400,000美元。

局限性

  • 这些发现受制于阿杜那单抗是否提供任何真实净健康获益的巨大不确定性。
  • 目前可用证据提示阿杜那单抗年定价56,000美元与其临床获益不合理匹配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. The objective of this analysis was to estimate its cost-effectiveness. METHODS: We developed a Markov model to compare aducanumab in addition to supportive care to supportive care alone over a lifetime horizon. Results were presented from both the health system and modified societal perspective. The model tracked the severity of disease and the care setting. Incremental cost-effectiveness ratios were calculated and a threshold analysis was conducted to estimate at what price aducanumab would meet commonly used cost-effectiveness thresholds. RESULTS: Using estimates of effectiveness based on pooling of data from both pivotal trials, patients treated with aducanumab spent 4 more months in earlier stages of Alzheimer disease. Over the lifetime time horizon, treating a patient with aducanumab results in 0.154 more quality-adjusted life-years (QALYs) gained per patient and 0.201 equal value of life-years gained (evLYG) per patient from the health care system perspective, with additional costs of approximately $204,000 per patient. The incremental outcomes were similar for the modified societal perspective. At the launch price of $56,000 per year, the cost-effectiveness ranged from $1.02 million per evLYG to $1.33 million per QALY gained from the health care system perspective and from $938,000 per evLYG to $1.27 million per QALY gained in the modified societal perspective. The annual price to meet commonly used cost-effectiveness thresholds ranged from $2,950 to $8,360, which represents a discount of 85%-95% off from the annual launch price set by the manufacturer. Using estimates of effectiveness based only on the trial that suggested a benefit, the mean incremental cost was greater than $400,000 per QALY gained. CONCLUSION: Patients treated with aducanumab received minimal improvements in health outcomes at considerable cost. This resulted in incremental cost-effectiveness ratios that far exceeded commonly used value thresholds, even under optimistic treatment effectiveness assumptions. These findings are subject to the substantial uncertainty regarding whether aducanumab provides any true net health benefit, but evidence available currently suggests that an annual price of aducanumab of $56,000 is not in reasonable alignment with its clinical benefits.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Whittington MD, Campbell JD, Rind D, et al. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease. Neurology. 2022. PMID: 35022306. doi:10.1212/WNL.0000000000013314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。